Federal momentum around psychedelic-assisted therapy accelerated in April 2026, when President Trump signed an executive order supporting state access programs, and the FDA announced fast-track vouchers for two psilocybin compounds and one MDMA-related drug. These are policy and regulatory developments, not yet approved treatments. Key takeaways FDA fast-track status is not approval. Three psychedelic compounds […]
Psilocybin and Psychedelics: Texas Pushes for Access